Nanoform Finland has announced a technology that can form biological nanoparticles as small as 50 nm and announced a new near-term business target for 2021 to deliver its first biologics

Alvotech and Alvotech & CCHT Biopharmaceutical, which is the China joint venture company of Alvotech hf. and Changchun High & New Technology Industries (Group) Inc., have partnered with Yangtze River

Immunicum has entered into an agreement with Van Herk Investments B.V. to acquire all of the shares in DCprime B.V., a Dutch clinical stage company developing cancer relapse vaccines aimed

Xbrane Biopharma has successfully carried out a directed share issue of approximately SEK 200 million at a subscription price of SEK 68.50 per share (the “Directed Share Issue”). The subscription

BioInvent International and CASI Pharmaceuticals, a U.S. biopharmaceutical company with an established clinical development and commercial infrastructure in China, have entered into an exclusive licensing agreement for the development and

Tromsø based ArcticZymes AS, a subsidiary of ArcticZymes Technologies, has entered into a supply and distribution agreement with precision medicine company Jiangsu Simcere Diagnostics, Nanjing, China. “This is just the

A new Swedish cell and gene therapy company, Elicera Therapeutics, has announced that it has completed its first share issue and secured 13.2 MSEK in financing. The company is based

Alvotech and DKSH have announced an expansion of their strategic partnership to commercialize six new biosimilar product candidates for the Asian markets. The initial pipeline contains biosimilar candidates addressing multiple

Vaccibody has announced that it has entered into an exclusive worldwide license and collaboration agreement with Genentech, a member of the Roche Group, for the development and commercialization of DNA-based

Immunicum has announced an update on its corporate and clinical development strategy. “With the information presented today at the corporate update event, we aim to provide an overview of our